<DOC>
	<DOCNO>NCT00937079</DOCNO>
	<brief_summary>The purpose study determine whether investigator ' new image modality ( 111In-exendin-4 ) advantage detect insulinomas comparison conventional imaging .</brief_summary>
	<brief_title>Whole Body 111In-exendin-4 Imaging Study Insulinoma Patients</brief_title>
	<detailed_description>Insulinomas arise pancreatic cell frequent hormone-active tumour pancreas . Insulinomas produce insulin become life threaten localise remove surgically . Complete tumour resection cure patient , hence surgery treatment choice begin malignant insulinomas . The potential surgical cure necessitates accurate tumour localisation surgery preoperative imaging facilitates detection small localise , multiple metastatic insulinomas . However , successful localisation insulinomas challenge problem since approximately 30 % insulinomas visualise radiographically . A novel nuclear medicine scan method use radioactive exendin-4 ( 111In-exendin-4 ) recently develop image insulinomas . 111In-exendin-4 accumulates specifically insulinoma cell via glucagon-like peptide-1 ( GLP-1 ) receptor . The accumulation 111In-exendin-4 visualise use special camera ( Single Photon Emission Computed Tomography ( SPECT ) camera ) detect radioactivity light tumour hot spot . The decision perform surgery independent study . If surgery perform small sample tumor use identify site 111In-exendin-4 bind tumor .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Hyperinsulinism</mesh_term>
	<mesh_term>Insulinoma</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Biochemically proven endogenous hyperinsulinism confirm hypoglycaemia neuroglycopenic symptom , inadequately high serum insulin Cpeptide concentration negative sulfonylurea screen well low serum betahydroxybutyrate concentration Able willing provide write informed consent Renal insufficiency ( creatinine &gt; 140 micromol/l ) Pregnancy positive pregnancy test perform patient without contraception age &lt; 50 year Allergy exendin4 ( ByettaÂ® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Glucagon-like peptide-1 receptor target</keyword>
	<keyword>Insulinoma imaging</keyword>
	<keyword>Exendin-4</keyword>
	<keyword>molecular imaging</keyword>
</DOC>